Integrated Single-Cell Atlases Reveal an Oral SARS-CoV-2 Infection and Transmission Axis

Competing Interest Statement

In the last year KMB has been a Scientific Advisor at Arcato Laboratories, Inc. and Coordinator at the Human Cell Atlas. For the last month MOF has served as a Scientific Advisor for PolyBio Research Foundation. In the last 3 years SAT has been remunerated for consulting by Roche and Genentech, and is a member of Scientific Advisory Boards at Biogen, GlaxoSmithKline and Foresite Labs.

Clinical Trial

NCT04348240; NCT02327884; NCT04105569

Funding Statement

These experiments were principally supported by grants and awards to K.M.B. (NIDCR K08 DE026537; AAP Sunstar Innovation Grant; L30 Loan Repayment Program for Clinical Researchers), and to B.M.W. (NIDCR Z01-DE000704) through the National Institutes of Health, National Institute of Dental and Craniofacial Research, Division of Intramural Research. Gingival scRNAseq was conducted by the UNC Advanced Analytics Core (Center for GI Biology and Disease; P30 DK034987). Additional support is from the Senior Research Training Fellowship by the American Lung Association (RT-575362), the Postdoctoral Research Fellowship by the Cystic Fibrosis Foundation (KATO20F0) to T.K, and NIH/NIDCR (K01DE027087 to J.T.M). The following investigators are also supported by the NIH Intramural Research Program: J.A.C., L.A.T., D.E.K., S.H., D.C., S.P., J.L.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The studies were conducted at two sites, independently utilizing clinical protocols which were approved by institutional review boards (IRB) at the respect institutions. UNC: Single cell gingival atlas constructed from human tissues was registered Clinicaltrials.gov ID: NCT04105569, approved by UNC IRB: 19-0183. Participant tissues included remnant oral specimens previously collected through the University of North Carolina Adams School of Dentistry Oral Pathology Biobank (UNC IRB 20-1501) or the Center for Oral and Systemic Diseases (COSD) Biorepository (UNC IRB 15-1814). Lab and project personnel were double-blinded and did not have access to PHI or any links to any PHI. Project members did not have interpersonal contact with patients that provided specimens. A subset of 10 samples from COVID-19 outpatients were collected (approved by UNC IRB 20-0792). The purpose of this study is to describe the epidemiology, clinical features, and immunological response to SARS-CoV-2 infection and develop new diagnostic tests focused on saliva. NIH: All patients seen at the author (B.M.W.) institute (NIDCR) reported herein provided informed consent prior to participation in NIH IRB-approved research protocols: NIH IRB 20-D-0094, NCT04348240; NIH IRB 15-D-0051, NCT02327884.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes